A
Agios Pharmaceuticals D
D
AGIO
43.900
USD
2.50
(6.04%)
قبل الجلسة
حجم التداول
115
الربح لكل سهم
-7
العائد الربحي
-
P/E
-6
حجم السوق
2,559,976,347
افتح حساب مع Tradeview
أصول ذات صلة الأخبار المقالات
العنوان: Agios Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.